Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/31890
Title: Evaluating sex as a predictive marker for response to bevacizumab in metastatic colorectal carcinoma: Pooled analysis of 3,369 patients in the ARCAD database.
Austin Authors: Margalit, Ofer;Harmsen, William S;Shacham-Shmueli, Einat;Voss, Molly M;Boursi, Ben;Wagner, Anna D;Cohen, Romain;Olswold, Curtis L;Saltz, Leonard B;Goldstein, Daniel A;Hurwitz, Herbert;Tebbutt, Niall C ;Kabbinavar, Fairooz F;Adams, Richard A;Chibaudel, Benoist;Grothey, Axel;Yoshino, Takayuki;Zalcberg, John;de Gramont, Aimery;Shi, Qian;Lenz, Heinz-Josef
Affiliation: Austin Health
Sheba Medical Center, Ramat-Gan, Israel; Tel-Aviv University, Tel-Aviv, Israel.
University of Melbourne, Australia
Department of Quantitative Science Research, Mayo Clinic, Rochester, MN, USA.
Sheba Medical Center, Ramat-Gan, Israel; Tel-Aviv University, Tel-Aviv, Israel.
Department of Quantitative Science Research, Mayo Clinic, Scottsdale, AZ, USA.
Department of Oncology, Division of Medical Oncology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Memorial Sloan Kettering Cancer Centre, New York, NY, USA.
Rabin Medical Centre, Petach Tikvah, Israel.
Duke Cancer Institute, Duke University, Durham, NC, USA.
David Geffen School of Medicine at University of California at Los Angeles, Los Angeles, CA, USA.
Cardiff University and Velindre Cancer Centre, Cardiff, UK.
Department of Medical Oncology, Franco-British Institute, Levallois-Perret, France.
West Cancer Center, Germantown, TN, USA.
Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Japan.
Department of Medical Oncology, Alfred Health and School of Public Health, Monash University, Melbourne, Australia.
Department of Medical Oncology, Franco-British Institute, Levallois-Perret, France.
Department of Quantitative Science Research, Mayo Clinic, Rochester, MN, USA.
Department of Gastrointestinal Oncology, Keck School of Medicine at USC, Los Angeles, CA, USA.
Issue Date: Jan-2023
metadata.dc.date: 2022
Publication information: European Journal of Cancer 2023; 178
Abstract: Previous studies suggest a possible sex-specific response to bevacizumab in metastatic colorectal carcinoma (mCRC), showing a benefit in males, while the effect in females is less significant.
URI: https://ahro.austin.org.au/austinjspui/handle/1/31890
DOI: 10.1016/j.ejca.2022.10.022
ORCID: 
Journal: European Journal of Cancer (Oxford, England : 1990)
Start page: 162
End page: 170
PubMed URL: 36446161
ISSN: 1879-0852
Type: Journal Article
Subjects: ARCAD
Age
Bevacizumab
Colorectal carcinoma
Metastatic
Sex
Bevacizumab/therapeutic use
Colorectal Neoplasms/drug therapy
Appears in Collections:Journal articles

Show full item record

Page view(s)

12
checked on Jun 9, 2023

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.